Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'
about
Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15Trial WatchApplication of IL-2 therapy to target T regulatory cell functionFrom systems to structure: bridging networks and mechanismInsights into cytokine-receptor interactions from cytokine engineeringRedirecting cell-type specific cytokine responses with engineered interleukin-4 superkinesConformational dynamics control ubiquitin-deubiquitinase interactions and influence in vivo signalingStructural basis of the proinflammatory signaling complex mediated by TSLPIL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapyTargeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy.Cytokine Activation by Antibody Fragments Targeted to Cytokine-Receptor Signaling Complexes.Citizens unite for computational immunology!A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activityHeat shock protein vaccination and directed IL-2 therapy amplify tumor immunity rapidly following bone marrow transplantation in mice.Extraordinary effects of unnatural pairingsPotent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cellsUtilizing combinatorial engineering to develop Tie2 targeting antagonistic angiopoetin-2 ligands as candidates for anti-angiogenesis therapyChallenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy.Equilibrium fluctuations of a single folded protein reveal a multitude of potential cryptic allosteric sites.In search of magic bullets: the golden age of immunotherapeutics.Targeting CD8+ T-cell tolerance for cancer immunotherapy.An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis.Conformational stabilization of ubiquitin yields potent and selective inhibitors of USP7.Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2.NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells.Mechanistic model of natural killer cell proliferative response to IL-15 receptor stimulationCytokines reinstate NK cell-mediated cancer immunosurveillance.Cytokine therapy reverses NK cell anergy in MHC-deficient tumorsCorrelating RANK ligand/RANK binding kinetics with osteoclast formation and function"Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosisAntibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms.Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumorsT cells in the control of organ-specific autoimmunityQuantitative Contribution of IL2Rγ to the Dynamic Formation of IL2-IL2R Complexes.Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps.Synthekines are surrogate cytokine and growth factor agonists that compel signaling through non-natural receptor dimers.Common gamma chain cytokines in combinatorial immune strategies against cancer
P2860
Q24301975-B43E066B-86D3-43C3-AD24-CAE5FE2E4331Q24618653-E96CD160-B85A-4EEB-85FF-3510B712C506Q26827327-D46A688B-8191-4792-885D-7A220147989DQ26830798-D2E6BD25-5A4F-46D9-B39D-57AE9CFF526BQ26852703-D2157058-3568-4879-A284-14EB0CF112ABQ27674753-FFF42FBC-3E3A-4506-B0DA-BF1AAA463A65Q27678806-F27F4890-1766-4B98-A95C-671A78F698B9Q27689496-C0B7A6E7-B335-48F6-B254-993DD09372D7Q28073154-0F64EAF0-5CDD-4BC2-BE04-F6ECC908C060Q28088784-C3E2E5A5-C3FA-4750-B4E6-7752870910C3Q30252860-180C6992-343B-40BC-AAD9-74E77E5CD9CCQ30381154-F9E38AE8-ED84-4797-9F0D-CA33BC38BCB7Q33361064-6BAC9A2A-A73B-4A05-9547-EECAECB1BB41Q33573863-C465307E-CA47-4CCF-AF78-CB24F568E92FQ33585305-2F2B8183-743E-47F5-94A1-31ECFBA9209BQ33675627-5AAC060B-7A8E-4612-B170-C51237529C37Q33705698-A3705F23-725E-4DB2-8110-14448646DF8DQ33779567-19855BCE-A9CD-4520-9224-FE73FA3B4B60Q33811204-15B7706A-A88A-4949-9CC5-42AF84097DC1Q33873731-95A957C4-E722-45F9-A890-89B2733F1CBDQ34323850-1350D1C4-9D51-459B-A4C6-3B5D187A9041Q34356481-128973D6-C4AC-46FA-AABB-070D8B95A300Q34432692-36A66157-1FAD-4637-B539-5478D5E33EC7Q34439798-B7F455D7-B6A1-4D85-A314-8E3C2AA83B42Q34487783-205AFDAD-309F-499B-8D90-49F0A4CD7174Q34651528-096EB1E6-B503-41A1-80CA-DBD716A1F9D1Q34884713-5EFD92F1-7268-48CC-8C81-1E9BCCB77944Q34998162-B3BA449C-3650-4333-8D6C-DEAC73D2403EQ35140082-A520E372-180F-43A3-88FD-F2AB5C7C1654Q35140125-D42D0867-80AE-48E8-9755-00FA56CE7B33Q35599724-74E4B739-EED5-447C-AC18-EB69E21CAAB2Q35608098-13E07020-BFF8-4260-A5C3-5FF715AF4549Q35630914-1CB83463-DB5A-476C-9433-CB1287B4D766Q35673240-7989F1CF-55BA-4C11-B8A7-E1CC78D22C63Q35836118-AC941343-BA6C-4AC2-A383-0447C002DDBCQ36022242-7D703125-C1C2-4552-872A-EAF63BF02055Q36024656-0E5BF3B7-222B-44BE-83ED-05E59B36B1C5Q36028807-545D8366-AC03-4E75-A934-1A0E91C9FC31Q36370053-EB8F983C-B24F-486B-82B6-D08356E1B19DQ36455872-EE197B48-DCE7-4E95-9B2E-FED4C86639CD
P2860
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'
@ast
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'
@en
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'
@nl
type
label
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'
@ast
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'
@en
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'
@nl
altLabel
Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
@en
prefLabel
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'
@ast
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'
@en
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'
@nl
P2093
P2860
P3181
P356
P1433
P1476
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'
@en
P2093
Aaron M Ring
Aron M Levin
C Garrison Fathman
Carsten Krieg
Darren L Bates
Gregory R Bowman
Ignacio Moraga
Jack T Lin
K Christopher Garcia
P2860
P2888
P304
P3181
P356
10.1038/NATURE10975
P407
P50
P577
2012-04-26T00:00:00Z
P5875
P6179
1036269489